61 Roitsch, S. et al. (2018) Detection by flow cytometry of anti-neutrophil cytoplasmic antibodies in a novel approach based on neutrophil extracellular traps. Autoimmunity 51, 288-296. doi: 10.1080/08916934.2018.1527317. Seibold, F. et al. (1998) pANCA represents a cross-reactivity to enteric bacterial antigens. J Clin Immunol 18, 153-160. doi: 10.1023/a:1023203118100. Geng, X. et al. (1998) Tropomyosin isoforms in intestinal mucosa: production of autoantibodies to tropomyosin isoforms in ulcerative colitis. Gastroenterology 114, 912-922. doi: 10.1016/s00165085(98)70310-5. Israeli, E. et al. (2005) Anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic antibodies as predictors of inflammatory bowel disease. Gut 54, 1232-1236. doi: 10.1136/gut.2004.060228. Smids, C. et al. (2017) The value of serum antibodies in differentiating inflammatory bowel disease, predicting disease activity and disease course in the newly diagnosed patient. Scand. J. Gastroenterol. 52, 1104-1112. doi: 10.1080/00365521.2017.1344875. Reese, G.E. et al. (2006) Diagnostic precision of anti-Saccharomyces cerevisiae antibodies and perinuclear antineutrophil cytoplasmic antibodies in inflammatory bowel disease. Am. J. Gastroenterol. 101, 24102422. doi: 10.1111/j.1572-0241.2006.00840.x. Dubinsky, M.C. et al. (2006) Serum immune responses predict rapid disease progression among children with Crohn’s disease: immune responses predict disease progression. Am. J. Gastroenterol. 101, 306-307. doi: 10.1111/j.1572-0241.2006.00456.x. Vermeire, S. et al. (2006) Laboratory markers in IBD: useful, magic, or unnecessary toys? Gut 55, 426-431. doi: 10.1136/gut.2005.069476. Joossens, S. et al. (2002) The value of serologic markers in indeterminate colitis: a prospective follow-up study. Gastroenterology 122, 1242-1247. doi: 10.1053/gast.2002.32980. Seow, C.H. et al. (2009) Novel anti-glycan antibodies related to inflammatory bowel disease diagnosis and phenotype. Am. J. Gastroenterol. 104, 1426-1434. doi: 10.1038/ajg.2009.79. Targan, S.R. et al. (2005) Antibodies to CBir1 flagellin define a unique response that is associated independently with complicated Crohn’s disease. Gastroenterology 128, 2020-2028. doi: 10.1053/j. gastro.2005.03.046. Chen, P. et al. (2020) Serum Biomarkers for Inflammatory Bowel Disease. Front. Med. (Lausanne) 7, 123. doi: 10.3389/fmed.2020.00123. Prideaux, L. et al. (2012) Serological antibodies in inflammatory bowel disease: a systematic review. Inflamm. Bowel Dis. 18, 1340-1355. doi: 10.1002/ibd.21903. van Schaik, F.D.M. et al. (2013) Serological markers predict inflammatory bowel disease years before the diagnosis. Gut 62, 683-688. doi: 10.1136/gutjnl-2012-302717. Choung, R.S. et al. (2016) Serologic microbial associated markers can predict Crohn’s disease behaviour years before disease diagnosis. Aliment. Pharmacol. Ther. 43, 1300-1310. doi: 10.1111/apt.13641. Bourgonje, A.R. et al. (2021) In-depth characterization of the serum antibody epitope repertoire in inflammatory bowel disease using phage-displayed immunoprecipitation sequencing. bioRxiv 2021; doi: https://doi.org/10.1101/2021.12.07.471581. Herold, K.C. et al. (2019) An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes. N. Engl. J. Med. 381, 603-613. doi: 10.1056/NEJMoa1902226. Al-Laith, M. et al. (2019) Arthritis prevention in the pre-clinical phase of RA with abatacept (the APIPPRA study): a multi-centre, randomised, double-blind, parallel-group, placebo-controlled clinical trial protocol. Trials 20, 429. doi: 10.1186/s13063-019-3403-7. Antibody signatures in IBD: developments and applications 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40
RkJQdWJsaXNoZXIy MjY0ODMw